Hayley Severance
Deputy Vice President, Global Biological Policy and Programs
Imagine this: A global pandemic that results in more than 850 million cases, and 60 million deaths is sparked by a novel enterovirus strain that was intentionally engineered by an extremist group using artificial intelligence–enabled capabilities. This is the fictional scenario that senior leaders grappled with during a tabletop exercise hosted by NTI in partnership with the Munich Security Conference (MSC) in February 2025.
The exercise explored opportunities and risks at the convergence of AI and life sciences (AIxBio), and the resulting report offers practical recommendations to prevent catastrophic misuse.
The key takeaway? The exploitation of AIxBio capabilities for harm is a plausible near-term risk—and the time for action is now.
To address these findings, the report authors issue four recommendations:
AIxBio capabilities hold immense promise—but they also introduce unprecedented risks. Without decisive action, the race for AI supremacy could devolve into a race to the bottom on safety. National governments, industry leaders, and philanthropic organizations must champion AIxBio innovation where safety and security are not afterthoughts, but core drivers of progress—essential to unlocking the full positive potential of these powerful technologies.
Sign up for our newsletter to get the latest on nuclear and biological threats.
The AIxBio field stands at a critical juncture where rapid capability advances are outpacing governance frameworks and safety measures. The next 18 months will likely prove pivotal in determining whether voluntary safety practices by AI companies, emerging evaluation frameworks, and international coordination efforts can keep pace with technological development.
Managed access will be critical for reducing biosecurity risks related to the misuse of biological AI tools. By working to develop best practices for each element of this framework—risk levels, tiered access, and practices to verify legitimacy—developers of biological AI tools and the broader life sciences community can reduce risks while maintaining the benefits of these tools.
Since the AIxBio Horizon Scan Winter 2025-2026 published in March 2026, there has been steady, incremental progress across AI-enabled biological tools. Protein design tools have continued to improve, agentic coding tools have matured in ways that lower barriers to computational biology, and commercial AI companies are making significant investments in the life sciences.
Sign up for regular updates on innovative, real-world solutions to existential threats.
{ location = 'https://www.nti.org/get-updates/' }, 300);">Get Updates